JAK2 V617F-positive essential thrombocythemia in a patient with Klinefelter syndrome: a case report

被引:3
作者
Yhim, Ho-Young [1 ]
Kim, Hee Sun [4 ]
Sohn, Ji-Youn [1 ]
Song, Min-Ju [1 ]
Lee, Na-Ri [1 ,3 ]
Song, Eun-Kee [1 ,3 ]
Choi, Sam-Im [2 ]
Yim, Chang-Yeol [1 ,3 ]
Kwak, Jae-Yong [1 ,3 ]
机构
[1] Chonbuk Natl Univ, Sch Med, Dept Internal Med, Div Hematol Oncol, Jeonju 561712, South Korea
[2] Chonbuk Natl Univ, Sch Med, Dept Lab Med, Jeonju 561712, South Korea
[3] Chonbuk Natl Univ, Sch Med, Adv Res Canc Ctr, Jeonju 561712, South Korea
[4] Jeonbuk Sci Coll, Dept Nursing, Jeongeup 580712, South Korea
关键词
TYROSINE KINASE JAK2; CANCER INCIDENCE; MYELOID METAPLASIA; MUTATION; MEN;
D O I
10.1016/j.cancergencyto.2010.01.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Klinefelter syndrome (KS) is the most commonly diagnosed X chromosome aneuploid syndrome among males. The association between hematologic malignancies such as non-Hodgkin lymphoma and leukemia and KS has been established recently on the basis of numerous case reports and a large cohort study. The risk of chronic myeloproliferative disease (MPD) as a hematologic malignancy in KS, however, has not been evaluated to date. Moreover, to our knowledge, there is only one case report that observed MPD in a patient with KS. Even though the Janus kinase 2 (JAK2) mutation was considered the primary cause in the pathogenesis of MPD, the mutation status was not described in that report. We found JAK2 V617F mutation-positive essential thromobocythemia (ET) in a patient with KS. To the best of our knowledge, this case represents the first case report of JAK2 V617F mutation in a patient with KS. Furthermore, we also suggest the hypothesis that X chromosome aneuploidy as a "pre-JAK2" cytogenetic change may be associated with the development of clonal hematopoiesis and carcinogenesis, because of the finding of higher oncogenic potential of extra X chromosome. In this study, we present the first report of JAK2 V617F-positive ET in a patient with KS, as well as a review of the relevant literature. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:162 / 165
页数:4
相关论文
共 50 条
  • [1] JAK2 V617F-positive essential thrombocythemia with subsequent development of immune thrombocytopenia A case report
    Oda, Yasuhiro
    Sato, Shuku
    Kanbe, Emiko
    Kamata, Wataru
    Okada, Satomi
    Tamai, Yotaro
    MEDICINE, 2019, 98 (44) : e17766
  • [2] Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden
    Lee, A-Jin
    Kim, Sang-Gyung
    Nam, Jun Yeb
    Yun, Jaehum
    Ryoo, Hun-Mo
    Bae, Sung Hwa
    BLOOD RESEARCH, 2021, 56 (04) : 259 - 265
  • [3] Oral squamous cell carcinoma with essential thrombocythemia and positive JAK2 (V617F) mutation
    Rahman, Kurnia H.
    Surboyo, Meircurius D. C.
    Radithia, Desiana
    Parmadiati, Adiastuti E.
    Wihandono, Asdi
    Ernawati, Diah S.
    JOURNAL OF TAIBAH UNIVERSITY MEDICAL SCIENCES, 2022, 17 (02): : 326 - 331
  • [4] JAK2 V617F positive essential thrombocythemia developing in a patient with CD5- chronic lymphocytic leukemia
    Wei Ju
    Wang Chun
    Qin You-wen
    Zhu Jun
    Gao Yang-rong
    Cai Qi
    Yan Shi-ke
    CHINESE MEDICAL JOURNAL, 2012, 125 (11) : 2076 - 2079
  • [5] JAK2 46/1 haplotype is associated with JAK2 V617F-positive myeloproliferative neoplasms in Japanese patients
    Tanaka, Mayumi
    Yujiri, Toshiaki
    Ito, Shunsuke
    Okayama, Naoko
    Takahashi, Toru
    Shinohara, Kenji
    Azuno, Yoichi
    Nawata, Ryouhei
    Hinoda, Yuji
    Tanizawa, Yukio
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2013, 97 (03) : 409 - 413
  • [6] Effects of Ruxolitinib on Immune Checkpoint Molecule Expression in JAK2 V617F-Positive Cells
    Fu, Jianzhu
    Cheng, Zhiyong
    Zhang, Lijun
    Wen, Xingchu
    Hao, Jianxue
    CLINICAL LABORATORY, 2024, 70 (10) : 1897 - 1907
  • [7] Mesenteric venous thrombosis secondary to an unsuspected JAK2 V617F-positive myeloproliferative disorder
    Bourke, M. G.
    Martin, S. T.
    O'Dwyer, M.
    Hanaghan, J.
    Bennani, F.
    Barry, M. K.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2012, 181 (02) : 285 - 287
  • [8] Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome
    Briere, Jean
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2007, 191 (03): : 535 - 548
  • [9] Bleeding complications after arthroscopy in a JAK2V617F-positive patient with essential thrombocythemia and acquired von Willebrand syndrome (AVWS)
    Rupa-Matysek, Joanna
    Lewandowski, Krzysztof
    Lewandowska, Maria
    Wojtasinska, Ewelina
    Wojtaszewska, Marzena Liliana
    Walczak, Michal
    Bykowska, Ksenia
    Komarnicki, Mieczyslaw
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (04) : 405 - 410
  • [10] Pronounced gut microbiota signatures in patients with JAK2V617F-positive essential thrombocythemia
    Eickhardt-Dalbge, Christina Schjellerup
    Ingham, Anna Cacilia
    Nielsen, Henrik V.
    Fuursted, Kurt
    Stensvold, Christen Rune
    Andersen, Lee O'Brien
    Larsen, Morten Kranker
    Kjaer, Lasse
    Christensen, Sarah Friis
    Knudsen, Trine Alma
    Skov, Vibe
    Ellervik, Christina
    Olsen, Lars Rnn
    Hasselbalch, Hans Carl
    Elmer Christensen, Jens Jrgen
    Nielsen, Xiaohui Chen
    MICROBIOLOGY SPECTRUM, 2023, 11 (05):